A Phase 1 Study of S-3304 in Patients With Solid Tumors

Shionogi

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Drug: S-3304

Study type: Interventional

Funder types: Industry

Identifiers

NCT00033215

0110P1416

Details and patient eligibility

About

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

Enrollment: 32 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

• Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s)
• Must be able to tolerate oral medication Exclusion criteria
• Patients with other serious illnesses
• Patients who are receiving treatments

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)